TY - JOUR
T1 - The confluence of stereotactic ablative radiotherapy and tumor immunology
AU - Finkelstein, Steven Eric
AU - Timmerman, Robert
AU - McBride, William H.
AU - Schaue, Drthe
AU - Hoffe, Sarah E.
AU - Mantz, Constantine A.
AU - Wilson, George D.
PY - 2011
Y1 - 2011
N2 - Stereotactic radiation approaches are gaining more popularity for the treatment of intracranial as well as extracranial tumors in organs such as the liver and lung. Technology, rather than biology, is driving the rapid adoption of stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), in the clinic due to advances in precise positioning and targeting. Dramatic improvements in tumor control have been demonstrated; however, our knowledge of normal tissue biology response mechanisms to large fraction sizes is lacking. Herein, we will discuss how SABR can induce cellular expression of MHC I, adhesion molecules, costimulatory molecules, heat shock proteins, inflammatory mediators, immunomodulatory cytokines, and death receptors to enhance antitumor immune responses.
AB - Stereotactic radiation approaches are gaining more popularity for the treatment of intracranial as well as extracranial tumors in organs such as the liver and lung. Technology, rather than biology, is driving the rapid adoption of stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), in the clinic due to advances in precise positioning and targeting. Dramatic improvements in tumor control have been demonstrated; however, our knowledge of normal tissue biology response mechanisms to large fraction sizes is lacking. Herein, we will discuss how SABR can induce cellular expression of MHC I, adhesion molecules, costimulatory molecules, heat shock proteins, inflammatory mediators, immunomodulatory cytokines, and death receptors to enhance antitumor immune responses.
UR - http://www.scopus.com/inward/record.url?scp=84855175162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855175162&partnerID=8YFLogxK
U2 - 10.1155/2011/439752
DO - 10.1155/2011/439752
M3 - Review article
C2 - 22162711
AN - SCOPUS:84855175162
SN - 1740-2522
VL - 2011
JO - Clinical and Developmental Immunology
JF - Clinical and Developmental Immunology
M1 - 439752
ER -